ERBB2 Inhibition and Heart Failure

著者: Gregory M. Coté, Douglas B. Sawyer, Bruce A. Chabner - New England Journal of Medicine, NEJM 2012 被引用: 101

The anti-ERBB2 antibody, trastuzumab, was developed to treat ERBB2-positive breast cancer. The cardiac toxicity it produced was unexpected but led to new insights about a role for ERBB2 in the response of the heart to stress.